

eTable S1. Reported symptoms by exposure condition^a

| | Unexposed to SMF N _{obs} = 134 | | | Exposed to SMF N _{obs} = 499 | | | Total N _{obs} = 633 | | | |
|--|--|---------|-------------------|--|---------|-------------------|---------------------------------|---------|-------------------|---------|
| | N _{obs} | (%) | N _{subj} | N _{obs} | (%) | N _{subj} | N _{obs} | (%) | N _{subj} | (%) |
| Any symptom within specified category | | | | | | | | | | |
| SMF target symptoms | 25 | (18.7%) | 25 | 141 | (28.3%) | 102 | 166 | (26.2%) | 124 | (37.5%) |
| SMF target - core symptoms | 1 | (0.8%) | 1 | 38 | (7.6%) | 31 | 39 | (6.2%) | 31 | (9.4%) |
| SGF target symptoms | 0 | (0.0%) | 0 | 2 | (0.4%) | 2 | 2 | (0.3%) | 2 | (0.6%) |
| A priori unrelated symptoms | 4 | (3.0%) | 4 | 29 | (5.8%) | 19 | 33 | (5.2%) | 22 | (6.6%) |
| Any symptoms | 28 | (20.9%) | 28 | 147 | (29.5%) | 105 | 175 | (27.7%) | 130 | (39.3%) |
| Specific symptom | | | | | | | | | | |
| Vertigo ^b | 0 | (0.0%) | 0 | 28 | (5.6%) | 23 | 28 | (4.4%) | 23 | (6.9%) |
| Nausea ^b | 0 | (0.0%) | 0 | 6 | (1.2%) | 6 | 6 | (1.0%) | 6 | (1.8%) |
| Head ringing ^b | 0 | (0.0%) | 0 | 5 | (1.0%) | 3 | 5 | (0.8%) | 3 | (0.9%) |
| Magnetophosphenes ^b | 1 | (0.8%) | 1 | 2 | (0.4%) | 2 | 3 | (0.5%) | 3 | (0.9%) |
| Metallic taste ^b | 0 | (0.0%) | 0 | 9 | (1.8%) | 9 | 9 | (1.4%) | 9 | (2.7%) |
| Headache ^c | 14 | (10.5%) | 14 | 57 | (11.4%) | 49 | 71 | (11.2%) | 62 | (18.7%) |
| Tiredness ^c | 12 | (9.0%) | 12 | 63 | (12.6%) | 47 | 75 | (11.9%) | 58 | (17.5%) |
| Concentration problems ^c | 3 | (2.2%) | 3 | 16 | (3.2%) | 14 | 19 | (3.0%) | 17 | (5.1%) |
| Vomiting ^c | 0 | (0.0%) | 0 | 0 | (0.0%) | 0 | 0 | (0.0%) | 0 | (0.0%) |
| Instability ^c | 0 | (0.0%) | 0 | 7 | (1.4%) | 6 | 7 | (1.1%) | 6 | (1.8%) |
| Lightheadedness ^c | 2 | (1.5%) | 2 | 19 | (3.8%) | 17 | 21 | (3.3%) | 19 | (5.7%) |
| Blurred vision ^c | 1 | (0.8%) | 1 | 2 | (0.4%) | 2 | 3 | (0.5%) | 3 | (0.9%) |
| Strange smell ^c | 1 | (0.8%) | 1 | 0 | (0.0%) | 0 | 1 | (0.2%) | 1 | (0.3%) |
| Tingling ^d | 0 | (0.0%) | 0 | 2 | (0.4%) | 2 | 2 | (0.3%) | 2 | (0.6%) |
| Muscle contractions ^d | 0 | (0.0%) | 0 | 0 | (0.0%) | 0 | 0 | (0.0%) | 0 | (0.0%) |
| Black spots ^e | 0 | (0.0%) | 0 | 2 | (0.4%) | 1 | 2 | (0.3%) | 1 | (0.3%) |
| Irritated eyes ^e | 1 | (0.8%) | 1 | 10 | (2.0%) | 7 | 11 | (1.7%) | 8 | (2.4%) |
| Irritated skin ^e | 1 | (0.8%) | 1 | 4 | (0.8%) | 3 | 5 | (0.8%) | 3 | (0.9%) |

| | | | | | | | | | | |
|--------------------------|---|--------|---|---|--------|---|---|--------|---|--------|
| Hot flashes ^e | 1 | (0.8%) | 1 | 7 | (1.4%) | 4 | 8 | (1.3%) | 4 | (1.2%) |
| Earache ^e | 1 | (0.8%) | 1 | 3 | (0.6%) | 3 | 4 | (0.6%) | 4 | (1.2%) |
| Palpitation ^e | 1 | (0.8%) | 1 | 5 | (1.0%) | 3 | 6 | (1.0%) | 4 | (1.2%) |

N_{obs} = number of observations; N_{subj} = number of individual subjects.

^a Results are based on an unbalanced study sampling design with repeated measures per subject.

^b SMF target core symptom, ^c SMF target symptom, ^d SGF target symptom, ^e a priori unrelated symptom